Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Dendritic Cell Vaccines against Her2/Her3 for the Treatment of Leptomeningeal Disease from Triple Negative Breast Cancer or HER2+ Breast Cancer

Trial Status: active

This phase I trial tests the safety, side effects, and best dose of dendritic cell vaccines against Her2/Her3 in treating patients with triple negative breast cancer or HER2+ breast cancer that has spread to the brain and spinal cord tissue (leptomeningeal metastasis). Dendritic cell vaccines work by boosting the immune system (a system in the body that protect against infection) to recognize and destroy the cancer cells. The dendritic cell vaccine is made utilizing blood cells collected from a procedure called leukapheresis. Infusing dendritic cell vaccines directly into the thin fluid-filled space between the lining of the spinal cord and brain via a surgically implanted reservoir under the scalp (Ommaya reservoir) may cause a stronger immune response, and may kill more tumor cells.